Onshoring pharmaceutical manufacturing has become a priority in the United States and is even backed by a $2 billion federal investment. Manufacturing capacity, according to a recent report, is readily available. SmartSkin Technologies announced Martin Van Trieste has joined its Board of Directors to offer his unique insights on how to maximize pharmaceutical manufacturing capacity and the executive-level considerations that go into those decisions.